Massachusetts’ largest life science employer has put more than 630,000 square feet of office space on the sublease market as part of efforts to consolidate the Japanese company’s U.S. corporate hub at ...

Scott Baird is a contributor with over a decade's experience writing about video games, along with board games and tabletop RPGs. Scott has previously worked for Dexerto, Cracked, Dorkly, and Gamepur.

Pharmaceutical companies need to spend money in order to make money, and the looming loss of patent exclusivity for numerous products has these companies out in force striking business deals to fill ...

Takeda (TAK) is rated 'HOLD' with a $12/share price target, reflecting limited upside and persistent execution risks. TAK's fundamentals are solid, but volatile earnings, poor forecast accuracy, and ...

Please provide your email address to receive an email when new articles are posted on . Qdenga offered protection against all four dengue serotypes for 7 years, Takeda said. The vaccine is not ...

Takeda Pharmaceutical Co.’s dengue vaccine has demonstrated strong protection against infection and hospitalization for seven years, marking the longest efficacy reported among any available dengue ...

Office: Takeda rare drug manufacturing facility. (Photo c/o Takeda Pharmaceuticals) Tokyo-based Takeda Pharmaceuticals Co. this month completed a $170 million expansion and renovation project on its ...

More than 130 employees in Massachusetts will be laid off from Takeda Pharmaceuticals next year, as the company discontinues its cell therapy efforts, a spokesperson confirmed. The Japanese ...

The Japanese company Takeda Pharmaceutical is one of the biggest employers in the Conejo Valley biotechnology sector. In Thousand Oaks, Takeda produces treatments for ultra-rare diseases, including a ...

Takeda Pharmaceutical offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. TAK's pipeline includes first-in-class and best-in-class ...

Takeda Pharmaceutical Co. announced on Thursday that it has recruited longtime Eli Lilly executive Rhonda Pacheco to lead its US business out of Cambridge. It’s a homecoming for Pacheco, a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Positive late-stage trial ...